376 related articles for article (PubMed ID: 12743136)
21. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer.
Tuxen MK; Sölétormos G; Petersen PH; Schioler V; Dombernowsky P
Gynecol Oncol; 1999 Jul; 74(1):12-22. PubMed ID: 10385546
[TBL] [Abstract][Full Text] [Related]
22. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
Timmerman D; Van Calster B; Jurkovic D; Valentin L; Testa AC; Bernard JP; Van Holsbeke C; Van Huffel S; Vergote I; Bourne T
J Clin Oncol; 2007 Sep; 25(27):4194-200. PubMed ID: 17698805
[TBL] [Abstract][Full Text] [Related]
23. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
24. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer screening: a look at the evidence.
Fields MM; Chevlen E
Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
[TBL] [Abstract][Full Text] [Related]
26. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.
Gemer O; Lurian M; Gdalevich M; Kapustian V; Piura E; Schneider D; Lavie O; Levy T; Fishman A; Dgani R; Levavi H; Beller U
Eur J Surg Oncol; 2005 Nov; 31(9):1006-10. PubMed ID: 16005601
[TBL] [Abstract][Full Text] [Related]
27. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
28. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
29. HE4 and ROMA index in Czech postmenopausal women.
Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
[TBL] [Abstract][Full Text] [Related]
30. [Early detection and preoperative diagnosis of ovarian carcinoma].
Kainz C
Wien Med Wochenschr; 1996; 146(1-2):2-7. PubMed ID: 8835487
[TBL] [Abstract][Full Text] [Related]
31. Serum CA-125 measurements > 65 U/mL. Clinical value.
Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
[TBL] [Abstract][Full Text] [Related]
32. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
33. Role of hysteroscopy with endometrial biopsy to rule out endometrial cancer in postmenopausal women with abnormal uterine bleeding.
Litta P; Merlin F; Saccardi C; Pozzan C; Sacco G; Fracas M; Capobianco G; Dessole S
Maturitas; 2005 Feb; 50(2):117-23. PubMed ID: 15653009
[TBL] [Abstract][Full Text] [Related]
34. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
35. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
Jacobs I
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
[No Abstract] [Full Text] [Related]
36. Screening for ovarian cancer.
Jacobs I; Oram D
Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382
[TBL] [Abstract][Full Text] [Related]
37. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
[TBL] [Abstract][Full Text] [Related]
38. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
39. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
40. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
